📊 UTMD Key Takeaways
Is Utah Medical Products Inc. (UTMD) a Good Investment?
UTMD maintains an exceptional financial fortress with zero debt, $85.8M cash reserves, and 29.3% net margins, providing substantial downside protection. However, declining revenue (-5.8% YoY) and sharply declining net income (-18.7% YoY) indicate operational headwinds outpacing revenue contraction, suggesting margin compression or business deterioration that warrants cautious positioning until operational trends stabilize.
Why Buy Utah Medical Products Inc. Stock? UTMD Key Strengths
- Fortress balance sheet with zero long-term debt and $85.8M cash (70% of assets)
- Exceptional profitability margins (57% gross, 30% operating, 29% net)
- Outstanding free cash flow generation with 37.2% FCF margin and minimal capex needs
- Extreme liquidity with 37.6x current ratio and 34.6x quick ratio
- Strong financial stability with total liabilities of only $3.3M
UTMD Stock Risks: Utah Medical Products Inc. Investment Risks
- Declining revenue (-5.8% YoY) indicating shrinking top-line in medical device market
- Net income declining 18.7% YoY vs only 5.8% revenue decline suggests margin compression or operational issues
- Moderate ROE/ROA (9-10%) indicates capital may not be efficiently deployed despite strong balance sheet
- Potential regulatory, competitive, or product-cycle headwinds in surgical instruments sector
- Zero insider buying activity in last 90 days during revenue/earnings decline
Key Metrics to Watch
- Quarterly revenue trend to confirm if decline is stabilizing or accelerating
- Gross and operating margin trends to identify source of earnings deterioration
- Product segment performance and mix shift analysis
- Cash flow generation sustainability amid declining earnings
Utah Medical Products Inc. (UTMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 37.2% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 37.62x current ratio provides a solid financial cushion.
UTMD Profit Margin, ROE & Profitability Analysis
UTMD vs Healthcare Sector: How Utah Medical Products Inc. Compares
How Utah Medical Products Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Utah Medical Products Inc. Stock Overvalued? UTMD Valuation Analysis 2026
Based on fundamental analysis, Utah Medical Products Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Utah Medical Products Inc. Balance Sheet: UTMD Debt, Cash & Liquidity
UTMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Utah Medical Products Inc.'s revenue has shown modest growth of 2% over the 5-year period. The most recent EPS of $1.16 reflects profitable operations.
UTMD Revenue Growth, EPS Growth & YoY Performance
UTMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9.8M | $2.6M | $0.82 |
| Q2 2025 | $10.0M | $3.0M | $0.94 |
| Q1 2025 | $9.7M | $3.0M | $0.92 |
| Q3 2024 | $10.0M | $3.6M | $1.02 |
| Q2 2024 | $10.4M | $3.5M | $0.98 |
| Q1 2024 | $11.3M | $4.0M | $1.09 |
| Q3 2023 | $12.5M | $3.9M | $1.08 |
| Q2 2023 | $12.9M | $3.5M | $1.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Utah Medical Products Inc. Dividends, Buybacks & Capital Allocation
UTMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Utah Medical Products Inc. (CIK: 0000706698)
📋 Recent SEC Filings
❓ Frequently Asked Questions about UTMD
What is the AI rating for UTMD?
Utah Medical Products Inc. (UTMD) has an AI rating of HOLD with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are UTMD's key strengths?
Claude: Fortress balance sheet with zero long-term debt and $85.8M cash (70% of assets). Exceptional profitability margins (57% gross, 30% operating, 29% net).
What are the risks of investing in UTMD?
Claude: Declining revenue (-5.8% YoY) indicating shrinking top-line in medical device market. Net income declining 18.7% YoY vs only 5.8% revenue decline suggests margin compression or operational issues.
What is UTMD's revenue and growth?
Utah Medical Products Inc. reported revenue of $38.5M.
Does UTMD pay dividends?
Utah Medical Products Inc. pays dividends, with $4.0M distributed to shareholders in the trailing twelve months.
Where can I find UTMD SEC filings?
Official SEC filings for Utah Medical Products Inc. (CIK: 0000706698) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is UTMD's EPS?
Utah Medical Products Inc. has a diluted EPS of $3.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is UTMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Utah Medical Products Inc. has a HOLD rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is UTMD stock overvalued or undervalued?
Valuation metrics for UTMD: ROE of 9.5% (sector avg: 15%), net margin of 29.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy UTMD stock in 2026?
Our dual AI analysis gives Utah Medical Products Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is UTMD's free cash flow?
Utah Medical Products Inc.'s operating cash flow is $14.7M, with capital expenditures of $371.0K. FCF margin is 37.2%.
How does UTMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 29.3% (avg: 12%), ROE 9.5% (avg: 15%), current ratio 37.62 (avg: 2).